Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 3,391 |
|
|||||
| News | - | ||||||
| Day High | 3.48 | Low High |
|||||
| Day Low | 3.37 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| NexImmune Inc | NEXI | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.04 | -1.17% | 3.37 | 16:00:04 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 3.44 | 3.37 | 3.48 | 3.37 | 3.41 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 122 | 3,391 | $ 3.41 | $ 11,577 | - | 1.2501 - 28.405 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:00:00 | 12 | $ 3.41 | USD |
NexImmune Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 3.57M | 1.06M | - | 0 | -62.51M | -59.07 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
NexImmune News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NEXI Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.13 | 3.89 | 3.06 | 3.52 | 18,939 | 0.24 | 7.67% |
| 1 Month | 5.57 | 5.72 | 3.01 | 3.95 | 38,457 | -2.20 | -39.50% |
| 3 Months | 14.01 | 19.6545 | 3.01 | 8.51 | 112,758 | -10.64 | -75.95% |
| 6 Months | 4.35 | 28.405 | 1.2501 | 8.55 | 1,258,209 | -0.98 | -22.53% |
| 1 Year | 9.92 | 28.405 | 1.2501 | 8.49 | 721,075 | -6.55 | -66.03% |
| 3 Years | 485.25 | 511.75 | 1.2501 | 28.05 | 552,786 | -481.88 | -99.31% |
| 5 Years | 575.25 | 695.00 | 1.2501 | 36.94 | 526,981 | -571.88 | -99.41% |
NexImmune Description
| NexImmune Inc is a clinical-stage biotechnology company engaged in developing immunotherapy to employ the body's T cells to generate an immune response that mimics natural biology. It creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. |
